Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D24EPJ
|
|||
| Drug Name |
CAT4001
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alpha-1 antitrypsin deficiency [ICD-11: 5C5A; ICD-10: E88.0, M79.3; ICD-9: 273.4] | Preclinical | [1] | |
| Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Preclinical | [1] | ||
| Company |
Catabasis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.